✳flâneur — a map of the web's best reading

Biotech Startups: Move Slow and Fix Things — Stanford Biotechnology Group

stanfordbiotechgroup.com · 3,037 words · saved by 2 readers

Startups are the primary source of biotechnology innovation. But funding for biotech entrepreneurs has been on a risky trajectory. What lies ahead? In our latest Biotech Insights blog, Joel Bateman, first-year MBA student at the Stanford GSB argues that incorrect parallels to the t

Biotech Startups: Move Slow and Fix Things Mar 10 Written By Joel Bateman Startups are the primary source of biotechnology innovation. But funding for biotech entrepreneurs has been on a risky trajectory. What lies ahead? In our latest Biotech Insights blog, Joel Bateman, first-year MBA student at the Stanford GSB argues that incorrect parallels to the tech industry and perceived falling costs associated with biotech startups have led to riskier and earlier funding for biotech startups. He outlines implications for the years ahead and offers ideas for biotech entrepreneurs to navigate the bump

Explore this link on the map →

saved by

related reading